ID   M249
AC   CVCL_D755
DR   ArrayExpress; E-MTAB-5493
DR   cancercelllines; CVCL_D755
DR   Cosmic; 1425353
DR   Cosmic; 1459652
DR   Cosmic; 1545618
DR   Cosmic; 1665014
DR   Wikidata; Q54903562
RX   PubMed=20406486;
RX   PubMed=20689758;
RX   PubMed=22515704;
RX   PubMed=22194965;
RX   PubMed=24735930;
RX   PubMed=29229836;
CC   Doubling time: 21.2 hours (PubMed=20406486).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20406486; PubMed=22194965).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965).
CC   Omics: Transcriptome analysis by RNAseq.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 13
RX   PubMed=20406486; DOI=10.1186/1479-5876-8-39;
RA   Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S.,
RA   Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N.,
RA   von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B.,
RA   Koya R.C., Mischel P.S., Lo R.S., Ribas A.;
RT   "Differential sensitivity of melanoma cell lines with BRAFV600E
RT   mutation to the specific Raf inhibitor PLX4032.";
RL   J. Transl. Med. 8:39.1-39.11(2010).
RX   PubMed=20689758; DOI=10.1593/neo.10414;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
RX   PubMed=22515704; DOI=10.1186/1476-4598-11-22;
RA   von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L.,
RA   Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C.,
RA   McCannel T.A., Izmailova E., Ribas A.;
RT   "Antitumor effects of the investigational selective MEK inhibitor
RT   TAK733 against cutaneous and uveal melanoma cell lines.";
RL   Mol. Cancer 11:22.1-22.9(2012).
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:E28973-E28973(2011).
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
RX   PubMed=29229836; DOI=10.1073/pnas.1712064115;
RA   Su Y.-P., Wei W., Robert L., Xue M., Tsoi J., Garcia-Diaz A.,
RA   Homet Moreno B., Kim J., Ng R.H., Lee J.W., Koya R.C.,
RA   Comin-Anduix B., Graeber T.G., Ribas A., Heath J.R.;
RT   "Single-cell analysis resolves the cell state transition and signaling
RT   dynamics associated with melanoma drug-induced resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017).